

BMJ Open

The impact of meridian balanced method electro-acupuncture on women with chronic pelvic pain: a three-arm randomised controlled pilot study.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2015-008621
Article Type:	Protocol
Date Submitted by the Author:	28-Apr-2015
Complete List of Authors:	Chong, Ooi Thye; University of Edinburgh, MRC Centre for Reproductive Health Critchley, Hilary; University of Edinburgh, MRC Centre for Reproductive Health Horne, Andrew; University of Edinburgh, MRC Centre for Reproductive Health Elton, Robert; University of Edinburgh, Centre for Population Health Sciences Haradsdottir, Erna; St. Columba's Hospice, Education and Research Fallon, Marie; University of Edinburgh, Cancer Research Centre
Primary Subject Heading:	Reproductive medicine
Secondary Subject Heading:	Qualitative research, Complementary medicine
Keywords:	Pain management < ANAESTHETICS, electro-acupuncture, chronic pelvic pain, context effects, mixed methods research

SCHOLARONE™
Manuscripts

STUDY PROTOCOL

TITLE: The impact of meridian balanced method electro-acupuncture on women with chronic pelvic pain: a three-arm randomised controlled pilot study

AUTHORS: Ooi Thye Chong¹, Hilary OD Critchley¹, Andrew W Horne¹, Robert Elton², Erna Haraldsdottir³, Marie Fallon⁴.

AFFILIATIONS: ¹MRC Centre for Reproductive Health, University of Edinburgh, UK; ²Centre for Population Health Sciences, University of Edinburgh, UK; ³St. Columba's Hospice, Edinburgh, UK; ⁴Cancer Research Centre, University of Edinburgh, UK.

CORRESPONDING AUTHOR:

Ooi Thye Chong

The University of Edinburgh

Simpson Centre for Reproductive Health, Room S7130

51 Little France Crescent

Edinburgh EH16 4SA

Tel: 0131 242 2687

Email: ochong@ed.ac.uk

KEY WORDS: Chronic pelvic pain, electro-acupuncture, meridian balanced method, context effects.

WORD COUNT: 2,858

ABSTRACT

Introduction: Chronic pelvic pain (CPP) affects 3-4% of women worldwide. Proven treatments for CPP are limited and unsatisfactory. The meridian balance method (BM) electro-acupuncture (EA) treatment (BMEA + Traditional Chinese Medicine Health Consult (TCM HC) may be effective for CPP. Previous EA studies have demonstrated an analgesic effect. Large-scale studies on acupuncture for other chronic pain conditions suggest that patient-healthcare provider interaction might play a role in pain reduction. We propose a pilot study to explore the effectiveness of the meridian BMEA treatment in managing women with CPP to inform a future large randomised controlled trial.

Methods and analysis: A three-armed randomised controlled pilot study is proposed with an aim to recruit 30 women with CPP in NHS Lothian. Randomisation will be to BMEA treatment, TCM HC or standard care (SC). Validated pain, physical and emotional functioning questionnaires will be administered to all participants at weeks 0, 4 (end of study) 8 and 12. Focus group discussions will be conducted when week twelve questionnaire are completed. The primary objective is to determine recruitment and retention rates. The secondary objectives are to assess the effectiveness and acceptability of the proposed methods of recruitment, randomisation, interventions and assessment tools.

Ethics and dissemination: Ethical approval has been obtained from the Scotland Research Ethics Committee (REC 14/SS/1022). Data will be published in peer-reviewed journals and presented at international conferences.

Trial registration number: NCT02295111

INTRODUCTION

Over 1 million women in the UK suffer from chronic pelvic pain (CPP). Annual healthcare expenditures are estimated at over £150 million.(1, 2) CPP impacts negatively on quality of life and work productivity.(3) CPP is associated with conditions such as endometriosis, painful bladder syndrome and irritable bowel syndrome. Up to 40% of women with CPP referred for diagnostic laparoscopy, have no apparent underlying cause identified for their painful symptoms.(4) The management of CPP is complex and treatment is often unsatisfactory.(5)

For this study we have chosen the meridian BM acupuncture because it is specifically indicated in painful conditions.(6) We believe that it maybe a helpful adjunct in managing CPP. The meridian BM acupuncture provides a systematic and interactive way to formulate a treatment strategy for pain management. The patient is instructed to point with one finger at the most painful area to identify the “sick” meridian. Once the “sick” meridian has been identified, a point on a healthy meridian will be used to balance the sick meridian. The acupuncturist presses on the chosen point and when the patient reports a reduction in pain level, the needle is inserted.

To maximise the specific effects of acupuncture needling, the needles may be stimulated manually (MA) or with micro electric current (EA). EA is the method of choice because of several reasons. Evidence from animals and human studies showed that both MA and EA produce analgesic effect. EA appears to be more effective than MA in some painful conditions. To obtain an analgesic effect in EA, the optimum time for the needle stimulation is 20 to 30 minutes and the frequencies set at 2Hz and 100Hz. (7, 8) Based on these parameters, it is impractical to be manually manipulating the acupuncture needles for 20-30

1 minutes and also be consistent. With EA one can precisely set both parameters
2
3 at every treatment. EA may be measured objectively, is easier to control and
4
5 standardize than MA. We will use the AS SUPER 4 Digital stimulator with four
6
7 outputs, with an alternating low (2Hz) and high frequency (100 Hz) facility that
8
9 is informed by the work of Han and his group.(9)
10
11

12
13
14 There is mounting evidence that acupuncture treatments for chronic pain, such
15
16 as low back pain,(10, 11) headache,(12, 13) shoulder and neck pain,(14) are
17
18 effective. Because acupuncture treatment is a complex intervention, the patient-
19
20 healthcare provider interactions (15) and expectation (16) might play a role in
21
22 its analgesic effect. Indeed, a study of pain management in patients with irritable
23
24 bowel syndrome demonstrated the effect of the former. Patients were
25
26 randomised on to waiting list (no placebo or interaction with healthcare
27
28 provider), therapeutic ritual (placebo sham acupuncture with limited
29
30 interaction) and a supportive relationship (placebo sham acupuncture with
31
32 enhanced relationship). The supportive relationship produced the most
33
34 adequate relief of symptoms and enhanced quality of life.(17)
35
36
37
38
39
40

41
42 The proposed pilot study will compare the specific effects of the meridian
43
44 balanced method (BM) electro-acupuncture needling + the context effects of a
45
46 TCM HC (BMEA treatment), with context effects of a TCM HC (patient-healthcare
47
48 provider interaction) and standard care. This study will enable us to tease out
49
50 the different components of acupuncture treatment that contribute to its
51
52 analgesic effect and to collect important information to inform a future definitive
53
54 RCT.
55
56
57
58
59
60

Objectives

Primary objective

The primary objective is to determine recruitment and retention rates in NHS Lothian within defined inclusion/exclusion criteria.

Secondary objectives

To determine the effectiveness and acceptability to participants of the proposed methods of recruitment, randomisation, interventions and assessment tools.

Endpoints

Primary endpoints

1. The proportion of eligible patients randomised into the study
2. The proportion of randomised patients who complete all treatment interventions and questionnaires at the final follow-up.

Secondary endpoints

Data on the effectiveness and acceptability of proposed methods of recruitment, randomisation, interventions and assessment tools.

METHODS AND ANALYSIS

Study design

This is a single centre, open, three-armed parallel randomised controlled pilot study comparing a meridian BM electro-acupuncture + TCM HC (Group 1), with TCM HC (Group 2) and SC (Group 3), (Figure 1), using a mixed methods approach.⁽¹⁸⁾ This includes quantitative method using validated questionnaires and qualitative method using focus groups post-study completion, as well as field notes and a reflective diary.

Subjects

1 30 women (aged greater than or equal to 18 years) with a history of CPP will be
2 invited to participate.
3
4
5

6 7 Sample size

8 We believe that a sample size of 30 patients is appropriate for a pilot study and
9 will allow estimation of percentage rates of recruitment and retention to within a
10 standard error of at most 10%.
11
12

13 Inclusion criteria

- 14 • Chronic pelvic pain longer than 6 months duration
- 15 • Average numerical pain score of at least 4 out of 10 in the previous week
- 16 • Able and willing to comply with intervention
- 17 • Women aged 18 and above

18 Exclusion criteria

- 19 • Pregnancy
- 20 • Malignancy
- 21 • Severe bleeding disorders (e.g. Type 2, 3 Von Willebrand disease)
- 22 • Regular anticoagulant administration
- 23 • Severe needle phobia
- 24 • A history of seizures
- 25 • A pace-maker in situ
- 26 • Moderate to severe psychiatric illness (currently under the care of a
27 Psychiatrist)
- 28 • Received electro-acupuncture and meridian BM within the last 6
29 months

Randomisation procedure

We will use an envelope randomisation system created by our statistician. There will be no stratification

Intervention

Eligible women will be randomised into meridian BMEA + TCM HC (Group 1), TCM HC (Group 2), and SC (Group 3). Participants in Group 1 will receive 8 treatments: twice a week x 4 weeks. Participants in Group 2 will receive 8 TCM HC: twice a week x 4 weeks. Participants in Group 3 will receive optimal standard care. (Table 1) The PI (OTC) who has been treating patients with acupuncture since 2002 will carry out all interventions. With permission from the participants, all interventions in Groups 1 and 2 will be audiotaped to ensure standardisation of procedures and techniques.

Table 1: Study Intervention and Treatment Schedule

		Group 1	Group 2	Group 3
	Baseline WK 0	BMEA +TCM HC	TCM HC alone	Standard Care
	Week 1	2 Sessions	2 Sessions	SC
	Week 2	2 Sessions	2 Sessions	SC
	Week 3	2 Sessions	2 Sessions	SC
	Week 4	2 Sessions	2 Sessions	SC
Total	4 Weeks	8 sessions	8 sessions	SC

Data collection

Screening

Eligible women will be consented and screened by a member of the research team. They will be randomised when they have passed screening. All data will be recorded on a case record form (CRF) and transferred to a secure database.

Assessment tools

Before randomisation, a questionnaire (Baseline week 0) will be given to all participants. This will include the following validated tools:

1. VAS scale
2. Brief Pain Inventory (BPI)
3. Hospital Anxiety and Depression Scale (HADS)
4. Quality Of Life: SF 12
5. Sexual Activity Questionnaire (SAQ)
6. Pain Catastrophising questionnaire (PCQ)
7. Work productivity & activity impairment questionnaire (WPAIQ)

The questionnaire at baseline (week 0) will include participants' demographic and relevant clinical information. The same questionnaire will be posted at weeks 4, 8 and 12 to all participants with an addressed envelope enclosed.

Focus groups

Three focus group discussions will be conducted after questionnaires in week twelve are completed. In order not to bias the group discussions, the PI (OTC) who provides the interventions will not be conducting the focus groups. A separate member of the research team will conduct the three focus group discussions lasting 90 minutes each. A content guide will be used in each group to focus the discussions,(19) which will provide additional data relevant to the study. The topic guide will focus on questions that will explore the participants'

1 perceived benefits or otherwise of the BMEA treatment (Group 1), TCM Health
2 Consultation (Group2) and NHS standard care (Group 3). The focus groups will
3 provide in-depth exploration of how and if the perceived benefits affect the
4 quality of their lives such as sleep quality, energy levels and sexual activities.
5 The discussions will be audiotaped, transcribed and thematically analysed.
6
7
8
9
10
11
12
13

14 Field notes and a reflexive diary

15 The PI will keep field notes and a reflexive diary during the course of the study.
16 After each intervention the PI will write notes related to her own observation of
17 salient events, discussions, remarks or behaviours that provide more
18 information about the participant and her experience of pain as well as the
19 possible impact or otherwise of the intervention. For example, the PI might
20 notice changes in facial colour or expression when a participant described how
21 the chronic pelvic pain impacted her life; or a participant who started a
22 treatment intervention apparently agitated but looking calmer at the close of the
23 session. Such data can add scope and depth as well as illuminate the different
24 aspects of the interventions and the patient-healthcare provider interactions
25 that might not be captured otherwise. In her reflexive diary the PI will make
26 note of her thoughts, feelings, and insights of such observations. This reflexive
27 practice involves the PI to be introspective, conscious of her role, reactions and
28 assumptions she brings to the intervention and the research process.(20)
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 Adverse events

52 When administered by an appropriately trained and qualified acupuncturist,
53 electro-acupuncture is safe and serious adverse events (SAEs) are not
54 anticipated. However, any SAEs that occur during the study will be reported in
55
56
57
58
59
60

1 the participant's medical record and followed up until resolution of the event.
2
3 We will also report it to the ACCORD Research Governance
4 (www.accord.ed.ac.uk) and QA Office based at the University of Edinburgh
5
6 within 24 hours. After randomisation, participants in Groups 1 and 2 will be
7
8 instructed to contact a member of the clinical research team if they have an event
9
10 that necessitates hospitalisation, or results in significant disability or incapacity.
11
12 In addition they will be asked about the occurrence of adverse effects at every of
13
14 the 8 visits during the study. Open-ended and non-leading verbal questioning of
15
16 the participant will be used to enquire about adverse events, or if they have been
17
18 admitted to hospital. If there is any doubt as to whether a clinical observation is
19
20 an AE, the event will be recorded.
21
22
23
24

25 End of study

26
27
28 The end of study is defined as the last participant's last visit.
29
30
31
32

33 **Proposed analyses**

34 Determine recruitment and retention rates

35
36 The recruitment rate will be calculated from the number of eligible patients in
37
38 the participant log. An acceptable recruitment rate is about 50%. We aim to
39
40 retain 90% of those recruited to the study. If retention rates are low, we will
41
42 explore the reasons why at the post study focus group discussions. Information
43
44 obtained in the discussions will be used to improve compliance in future study.
45
46
47
48
49
50

51 Effectiveness and acceptability of proposed methods of recruitment, 52 randomisation, BMEA treatments, TCM HC and assessment tools

53
54
55 Effectiveness will be measured by reductions in pain and associated symptoms
56
57 covered in the questionnaires. Additional information on effectiveness, not
58
59
60

1 covered in the questionnaires, will be captured in the focus groups. The
2
3 appropriateness of assessment tools used can be assessed through examination
4
5 of data completion and patterns of missing data. The focus groups will be
6
7 complementary to understanding if the tools chosen are appropriate and will
8
9 also provide information on acceptability of recruitment, randomisation and the
10
11 treatments themselves.
12

13 14 15 16 17 **ETHICS AND DISSEMINATION**

18 Ethical approval has been obtained from the Scotland Research Ethics
19
20 Committee (REC 14/SS/1022). Data will be presented at international
21
22 conferences and published in peer-reviewed journals. We will make the
23
24 information obtained from the study available to the public through national
25
26 bodies and charities.
27
28

29 30 31 32 **DISCUSSION**

33 We believe that a definitive evaluation of the effectiveness of the meridian BM
34
35 electro-acupuncture treatment in the management of CPP requires a multicentre
36
37 randomised controlled trial (RCT). We anticipate potential difficulties in a large
38
39 RCT in acupuncture for chronic pain and therefore we've designed this pilot
40
41 RCT in acupuncture for chronic pain and therefore we've designed this pilot
42
43 study to evaluate its feasibility.
44
45

46
47 Both MA (21) and EA (22, 23) are safe when performed by appropriately trained
48
49 acupuncturists. However because of some theoretical safety concerns, we have
50
51 erred on the side of caution to exclude for example, patients who have a history
52
53 of seizures or implanted pace maker.
54
55
56
57
58
59
60

1 The meridian BM acupuncture, deeply rooted in classical Chinese medicine
2 (CCM) is used clinically in pain management. According to CCM theory, pain
3 results from blocked meridians leading to an imbalance in the system. On the
4 surface of the body is a network of 12 meridians (6 yin and 6 yang) that connect
5 acupuncture points together.(24) Theoretically, these meridians act as a conduit
6 between the surface of the body and the internal organs. The meridian BM
7 method acupuncture treats pain by balancing these meridians, for example using
8 a “healthy” yin meridian to balance a “blocked” yang meridians. (25) However
9 there are considerable skepticisms and controversies surrounding these theories
10 and the existence as physical entities of acupuncture points and the meridian
11 system. Despite efforts to understand these systems, there is no agreement as to
12 what they constitute.(26, 27) Indeed, the PI (OTC) argues that it is more useful
13 to view these systems as conceptual framework that guides the clinical practice
14 of acupuncture rather than arguing if they exist. Tangentially related to this
15 view is work undertaken by Langevin whereby it is hypothesized that
16 acupuncture points and meridians has correspondence to the connective tissue
17 (28) and not directly as drawn out in Chinese medicine text.

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41 A survey of the literature indicates that this is the first study to investigate the
42 effectiveness of the meridian BM electro-acupuncture treatment for chronic
43 pelvic pain in women using a mixed methods approach. This mixed methods
44 approach utilises validated questionnaire and focus group discussions, field
45 notes and a reflexive diary. Undertaking a mixed methods approach is one of the
46 strengths of the study because we are examining the feasibility of studying a
47 complex intervention, which involves a number of phenomena which include:
48 TCM health consult, electro-acupuncture, context effects and patient
49 expectations. Alongside an understanding of participants’ perceived benefits or

1 otherwise of the interventions, this methodology will also help us to understand
2 the role of the researcher in the study intervention. The focus group discussions
3 will capture participants' subjective experience of the study intervention.
4
5
6
7

8
9 It is generally considered that the gold standard in effectiveness RCTs is the use
10 of a placebo control for the study intervention. However, our pilot study does
11 not employ a placebo (sham acupuncture treatment) for several reasons. A
12 considerable body of evidence from large-scale effectiveness studies have
13 demonstrated that sham acupuncture treatments as controls are problematic.
14 For some chronic pain conditions, the observed effects of acupuncture
15 treatments are larger in usual care controls when compared with sham controls.
16 This might suggest that sham acupuncture treatments have physiological effects,
17 and thus not inert. Past sham controlled studies have employed techniques such
18 as shallow needling, and needling with a retractable needle or toothpick.(10, 29)
19 Such techniques create a sensation not dissimilar to light touch which has some
20 data to show that it has physiological effects.(30) It is also conceivable and
21 probable that shallow needling and needling with a retractable needle elicit
22 similar physiological effects as deep needling. These sham acupuncture
23 techniques are therefore inappropriate. We feel that until better sham
24 techniques are available, it is prudent to design a study that does not employ a
25 placebo control.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 Context effects such as expectancy (31) treatment rituals (32) or patient-
50 provider interactions (15, 17) have been shown to have an impact on the
51 experience of pain. These might have confounded past studies and might explain
52 the small effect sizes when sham acupuncture treatments were compared to true
53 acupuncture treatments. Attempting to separate the context effects of
54
55
56
57
58
59
60

1 acupuncture treatment from the specific effects of acupuncture needling
2 presents a major challenge in this area of research. In response, we have
3 designed a three arm RCT to address these challenges. The first arm includes
4 acupuncture needling, electro-stimulation (specific effects of needling) and the
5 patient-healthcare provider interactions (context effects) via a traditional
6 Chinese medicine consult (TCM HC). Each consult will evolve based on
7 participants' health status but will include typically tongue diagnosis, breath-
8 work and advice on self-care. Arm 2 (participants receive only TCM HC) controls
9 for the patient-healthcare provider interactions (context effect). Participants in
10 arm 3 (standard care) will receive the standard NHS care for CPP. Having these
11 2 control groups is likely to yield the true effect size of the specific effect of
12 electro-acupuncture needling and the non-specific (context effect) of the patient-
13 healthcare provider interactions. We acknowledge that this pilot study is
14 investigating only one aspect of the several context effects of acupuncture
15 treatment. However, we believe that understanding the clinical outcome of the
16 patient-healthcare provider relationship will create a critical mass of literature
17 to influence the education of future generations of healthcare professionals. The
18 UK SIGN 136 guideline for the management of chronic pain acknowledged that
19 while preliminary data showed that the nature of such a relationship could
20 influence clinical outcome, there is not enough high quality studies to
21 recommend widespread training.(33) (Management of chronic pain. Edinburgh: SIGN;
22 December 2013]. Available from URL: <http://www.sign.ac.uk>. Accessed March 2015)
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 In conclusion, our pilot study protocol will enable us to determine the retention
52 and recruitment rate as well as the patients' experience of the study
53 intervention. It will help us gain better insight into the impact of meridian BM
54 electro-acupuncture needling and the patient-practitioner relationship on
55
56
57
58
59
60

1 chronic pelvic pain in women.
2
3
4

5 **AUTHORS' CONTRIBUTIONS**
6

7 OTC: research, contribution of original material, editing and approval of final
8 manuscript; HODC, AH, MF: research, contribution of original material, editing
9 and approval of final manuscript; RE, EH: editing and approval of final
10 manuscript.
11
12
13
14
15
16
17
18

19 **ACKNOWLEDGEMENTS**
20

21 We wish to acknowledge Mrs Sheila Milne for secretarial support and Mr Ronnie
22 Grant for graphical assistance.
23
24
25
26
27

28 **FUNDING**
29

30 This work is partly supported by the Barbour Watson Trust and Edinburgh
31 Palliative and Supportive Care Research Fund.
32
33
34
35
36

37 **COMPETING INTERESTS**
38

39 None.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Daniels J, Khan KS. Chronic pelvic pain in women. *BMJ*. 2010;341.
2. Latthe P, Latthe M, Say L, et al. WHO systematic review of prevalence of chronic pelvic pain: a neglected reproductive health morbidity. *BMC Public Health*. 2006;6(1):177.
3. Daniels J, Gray R, Hills RK, et al. Laparoscopic uterosacral nerve ablation for alleviating chronic pelvic pain: A randomized controlled trial. *JAMA*. 2009;302(9):955-61.
4. Howard FM. The role of laparoscopy as a diagnostic tool in chronic pelvic pain. *Best Practice & Research Clinical Obstetrics & Gynaecology*. 2000;14(3):467-94.
5. Cheong Y, Stones WR. Chronic pelvic pain: aetiology and therapy. *Best Pract Res Clin Obstet Gynaecol*. 2006;20(5):695-711.
6. Tan R. Dr. Tan's Strategy of Twelve Magical Points. San Diego California. 2003.
7. Thomas M, Lundberg T. Importance of modes of acupuncture in the treatment of chronic nociceptive low back pain. *Acta Anaesthesiol Scand*. 1994;38(1):63-9.
8. Ulett GH, SP, Han, JS. Electroacupuncture: mechanisms and clinical application. *Biol Psychiatry*. 1998;44(2):129-38.
9. Han JS, Terenius L. Neurochemical basis of acupuncture analgesia. *Annu Rev Pharmacol Toxicol*. 1982;22:193-220.
10. Haake M, Müller H, Schade-Brittinger C, et al. German acupuncture trials (gerac) for chronic low back pain: Randomized, multicenter, blinded, parallel-group trial with 3 groups. *Archives of Internal Medicine*. 2007;167(17):1892-8.
11. Brinkhaus B, Witt CM, Jena S. et al. Acupuncture in patients with chronic low back pain: A randomized controlled trial. *Arch Intern Med*. 2006;166(4):450-7.
12. Melchart D, Streng A, Hoppe A, et al. The acupuncture randomised trial (ART) for tension-type headache--details of the treatment. *Acupunct Med*. 2005;23(4):157-65.
13. Endres H, Bowing G, Diener HC. et al. Acupuncture for tension-type headache: a multicentre, sham-controlled, patient-and observer-blinded, randomised trial. *J Headache Pain*. 2007;8(5):306-14.
14. Witt C, Jena S, Brinkhaus B. et al. Acupuncture for patients with chronic neck pain. *Pain*. 2006;125(1-2):98-106.
15. Paterson C, Dieppe P. Characteristic and incidental (placebo) effects in complex interventions such as acupuncture. *Br Med J*. 2005;330(7501):1202-5.

16. Kong J, Kaptchuk TJ, Polich G, *et al.* An fMRI study on the interaction and dissociation between expectation of pain relief and acupuncture treatment. *Neuroimage*. 2009;47(3):1066-76.
17. Kaptchuk T, Kelley, JM, Conboy, L. et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. *BMJ*. 2008;336(7651):999-1003.
18. Creswell J, Clark VLP. *Designing and Conducting Mixed Methods Research*. 2 ed: Sage 2011: 2-5.
19. Morgan DL. *Focus Groups As Qualitative Research*. Second ed. London: Sage Publications; 1997: 47-48.
20. Finlay L. "Outing" the researcher: The provenance, process, and practice of reflexivity. *Qual Health Research* 2002, 12:531. *Qualitative Health Research [Internet]*. 2002.
21. MacPherson H, Thomas K, Walters S. et al. The York acupuncture safety study: prospective survey of 34 000 treatments by traditional acupuncturists. *BMJ*. 2001;323(7311):486-7.
22. Cummings M. Safety aspects of electroacupuncture. *Acupunct Med*. 2011;29(2):83-5.
23. Thompson JW, Cummings M. Investigating the safety of electroacupuncture with a Picoscope. *Acupunct Med*. 2008;26(3):133-9.
24. Deadman P, Al-Khafaji M, & Baker K. *A Manual of Acupuncture*. England, UK: Journal of Chinese Medicine Publications; 2001:13-16.
25. Twicken D. *I Ching Acupuncture: The Balance Method*. Philadelphia, United States: Singing Dragon; 2012:153-162.
26. Ulett GA, Han J, Han S. Traditional and evidence-based acupuncture: history, mechanisms, and present status. *South Med J*. 1998;91(12):1115-20.
27. Pandolfi M. The autumn of acupuncture. *Eur J Intern Med*. 2012;23(1):31-3.
28. Langevin HM, Yandow JA. Relationship of acupuncture points and meridians to connective tissue planes. *Anat Rec*. 2002;269(6):257-65.
29. Langevin H, Wayne PM, MacPherson H. et al. *Paradoxes in Acupuncture Research: Strategies for Moving Forward*. *Evid Based Complement Alternat Med*. 2010.
30. Lund I, Lundeberg T. Are minimal, superficial or sham acupuncture procedures acceptable as inert placebo controls? *Acupunct Med*. 2006;24(1):13-5.
31. Kong J, Kaptchuk TJ, Polich G, *et al.* Expectancy and treatment interactions: a dissociation between acupuncture analgesia and expectancy evoked placebo analgesia. *Neuroimage*. 2009;45(3):940-9.

1 32. Kaptchuk TJ. The placebo effect in alternative medicine: can the
2 performance of a healing ritual have clinical significance? Ann Intern Med.
3 2002;136(11):817-25.
4

5 33. Management of Chronic Pain, <UK SIGN136.pdf>. Available from URL:
6 <http://www.sign.ac.uk>. Accessed March 2015
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Figure Legend

Figure 1. Flow of participants through the study

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure 1



BMJ Open

The BMEA Study: The impact of meridian balanced method electro-acupuncture on women with chronic pelvic pain: a three-arm randomised controlled pilot study using a mixed methods approach.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-008621.R1
Article Type:	Protocol
Date Submitted by the Author:	03-Sep-2015
Complete List of Authors:	Chong, Ooi Thye; University of Edinburgh, MRC Centre for Reproductive Health Critchley, Hilary; University of Edinburgh, MRC Centre for Reproductive Health Horne, Andrew; University of Edinburgh, MRC Centre for Reproductive Health Elton, Robert; University of Edinburgh, Centre for Population Health Sciences Haradsdottir, Erna; St. Columba's Hospice, Education and Research Fallon, Marie; University of Edinburgh, Cancer Research Centre
Primary Subject Heading:	Reproductive medicine
Secondary Subject Heading:	Qualitative research, Complementary medicine
Keywords:	Pain management < ANAESTHETICS, electro-acupuncture, chronic pelvic pain, context effects, mixed methods research

SCHOLARONE™
Manuscripts

STUDY PROTOCOL

TITLE

The BMEA Study: The impact of meridian balanced method electro-acupuncture on women with chronic pelvic pain: a three-arm randomised controlled pilot study using a mixed methods approach.

AUTHORS: Ooi Thye Chong¹, Hilary OD Critchley¹, Andrew W Horne¹, Robert Elton², Erna Haraldsdottir³, Marie Fallon⁴.

AFFILIATIONS: ¹MRC Centre for Reproductive Health, University of Edinburgh, UK; ²Centre for Population Health Sciences, University of Edinburgh, UK; ³St. Columba's Hospice, Edinburgh, UK; ⁴Cancer Research Centre, University of Edinburgh, UK.

CORRESPONDING AUTHOR:

Ooi Thye Chong

The University of Edinburgh

Simpson Centre for Reproductive Health, Room S7130

51 Little France Crescent

Edinburgh EH16 4SA

Tel: 0131 242 2687

Email: ochong@ed.ac.uk

KEY WORDS: Chronic pelvic pain, electro-acupuncture, meridian balanced method, context effects.

WORD COUNT: 4972

ABSTRACT

Introduction: Chronic pelvic pain (CPP) affects 3-4% of women worldwide. Proven treatments for CPP are limited and unsatisfactory. The meridian balance method (BM) electro-acupuncture (EA) treatment (BMEA + Traditional Chinese Medicine Health Consult (TCM HC) may be effective for CPP. Previous EA studies have demonstrated an analgesic effect. Large-scale studies on acupuncture for other chronic pain conditions suggest that patient-healthcare provider interaction might play a role in pain reduction. We propose a pilot study to explore the effectiveness of the meridian BMEA treatment in managing women with CPP to inform a future large randomised controlled trial.

Methods and analysis: A three-armed randomised controlled pilot study is proposed with an aim to recruit 30 women with CPP in NHS Lothian. Randomisation will be to BMEA treatment, TCM HC or standard care (SC). Validated pain, physical and emotional functioning questionnaires will be administered to all participants at weeks 0, 4, 8 and 12. Focus group discussions will be conducted when week twelve questionnaires are completed. The primary objective is to determine, recruitment and retention rates. The secondary objectives are to assess the effectiveness and acceptability of the proposed methods of recruitment, randomisation, interventions and assessment tools.

Ethics and dissemination: Ethical approval has been obtained from the Scotland Research Ethics Committee (REC 14/SS/1022). Data will be published in peer-reviewed journals and presented at international conferences.

Trial registration number: NCT02295111

Registry Name: ClinicalTrials.gov

Strengths and limitations of this study

- We anticipate that there maybe potential difficulties in conducting a large RCT for chronic pelvic pain using acupuncture
- The study is designed to assess the practical feasibility
- This is the first pilot study to employ the meridian balanced method acupuncture style for chronic pelvic pain
- We will conduct focus groups to assess the acceptability of the interventions and the schedule
- We recognise that the context in which the intervention is given might play a role in pain reduction, thus the study is designed to separate the specific effects of acupuncture needling from the context effects of acupuncture treatment.
- We acknowledge that failure to use sham acupuncture as a control could be seen as a weakness in our study, however, well-designed large-scale RCTs of acupuncture have shown that sham acupuncture could lead to an underestimation of treatment effectiveness.

INTRODUCTION

Over 1 million women in the UK suffer from chronic pelvic pain (CPP). Annual healthcare expenditures are estimated at over £150 million.(1, 2) CPP impacts

1 negatively on quality of life and work productivity.(3) CPP is associated with
2 conditions such as endometriosis, painful bladder syndrome and irritable bowel
3 syndrome. Up to 40% of women with CPP referred for diagnostic laparoscopy,
4
5
6
7
8 have no apparent underlying cause identified for their painful symptoms.(4) The
9
10 management of CPP is complex and treatment is often unsatisfactory.(5) We
11
12 believe that acupuncture may be a helpful adjunct in the management of CPP.
13
14 Our hypothesis is that the meridian BMEA treatment alleviates pain, and
15
16 improves physical and emotional functioning, in women with CPP.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Meridian Balance Method (BM) Acupuncture

For this study we have chosen the meridian Balance Method (BM) acupuncture (6) which is a novel approach for the management of painful conditions. With this style of acupuncture, pain relief is expected once the needle is inserted in the appropriately chosen acupuncture points.

The meridian BM acupuncture offers an interactive and systematic strategy to formulate a treatment plan through the diagnosis of the sick meridian and selection of a healthy meridian and acupuncture points. Meridian balancing has been well described in the Huang Di Nei Jing, a seminal classical Chinese medicine (CCM) text (7) as well as in modern text. (6, 8, 9) Modern Traditional Chinese Medicine (TCM) emerges out of the standardization of CCM, and is one of the most popular approaches used by professional acupuncturists in the United Kingdom. In comparison, the meridian BM acupuncture is relatively unknown and rarely included in the curriculum of Chinese medicine schools. The meridian BM acupuncture has several key features: the 5 systems of meridian balancing (Table 1), Mirror and Image methods. (6)

The Five Systems of Meridian Balance Method

The meridian BM acupuncture utilizes the five systems shown in Table 1. Each sick meridian (painful area) can be balanced (treated) by any one of the five systems. For example the “Sick Meridian”, Lung meridian (Lung Hand Taiyin) can be balanced by systems 1, 2, 3, 4 or 5.

Table 1: Five Systems of Meridian Balance Method

	System 1	System 2	System 3	System 4	System 5

Sick Meridian	Name Sharing	Branching Bie Jing	Interior/ Exterior Biao Li	Clock Opposite	Clock Neighbour
LU/Hand Taiyin	SP	UB	LI	UB	LR
LI/Hand Yangming	ST	LR	LU	KI	ST
ST/Foot Yangming	LI	PC	SP	PC	LI
SP/Foot Taiyin	LU	SI	ST	TH	HT
HT/Hand Shaoyin	KI	GB	SI	GB	SP
SI/Hand Taiyang	UB	SP	HT	LR	UB
UB/Foot Taiyang	SI	LU	KI	LU	SI
KI/Foot Shaoyin	HT	TH	UB	LI	PC
PC/Hand Jueyin	LR	ST	TH	ST	KI
TH/Hand Shaoyang	GB	KI	PC	SP	GB
GB/Foot Shaoyang	TH	HT	LR	HT	TH
LR/Foot Jueyin	PC	LI	GB	SI	LU

Meridian Names:

LU= Lung, LI=Large Intestine, ST= Stomach, SP= Spleen, HT= Heart, SI= Small Intestine, UB= Urinary Bladder, KI= Kidney, PC= Pericardium, TH= Triple Heater, GB= Gallbladder, LR= Liver.

Image And Mirror Methods

Once the healthy meridian for treating the sick meridian is identified, the Image or Mirror Method is employed to locate more precisely the areas of the body to be treated. The acupuncturist palpates the meridian of the identified area for the best acupuncture point(s) that will relieve the pain. Thus point selections are individualised.

The Image method maps the relationship between the limb and the whole body (Table 2). For example, the hand images the genitals, coccyx and sacrum and the forearm images the lower abdomen and lower back. (6)

Table 2: Image Method (Upper Limb to Head and Trunk)

Needed Area	Sick Area (Image)
Finger	Testicles & anus
Hand	Genitals, coccyx, sacrum
Wrist	Bladder area, lumbo-sacral area
Forearm	Lower abdomen, lower back

Elbow	Umbilicus level, lumbar 2, waist
Upper arm	Upper abdomen, rib cage, chest, mid-upper back
Shoulder	Neck, jaw, base of skull
Top of shoulder	Top of head

The Mirror method “maps” one limb onto another or one part of the body to another part of the body. (Table 3) For examples, the finger mirrors the toe and the front mirrors the back of the body and vice versa. (10)

The Image and Mirror knowledge has also been described in Su Wen, another seminal classical Chinese medicine text that detailed the relationship between back and front, up and down and left and right. (11) This kind of mapping is known in the present day as somatotopy where a specific point of the body can be projected to a specific point in the primary somatosensory cortex of the brain. (12)

Table 3: Mirror Method And Reverse Mirror Method

Mirror Method	Reverse Mirror Method
Finger ↔ Toe	Finger ↔ Top of Hip
Hand ↔ Foot	Hand ↔ Hip
Wrist ↔ Ankle	Wrist ↔ Hip Joint
Forearm ↔ Lower Leg	Forearm ↔ Thigh
Elbow ↔ Knee	Elbow ↔ Knee
Upper Arm ↔ Thigh	Upper Arm ↔ Lower Leg
Shoulder ↔ Hip	Shoulder ↔ Ankle
Back ↔ Front (Du ↔ Ren)	Front ↔ Back (Ren ↔ Du)

Electro-Stimulation

To maximise the specific effects of acupuncture needling, the needles may be stimulated manually (MA) or with micro electric current (EA). Although there have been no studies to show that EA enhances the analgesic effect of the meridian BM acupuncture, it is, however, the method of choice for several reasons. Evidence from animal and human studies showed that both MA and EA

1 produce analgesic effect. (13) EA appears to be more effective than MA in some
2 painful conditions. To obtain an analgesic effect in EA, the optimum time for the
3 needle stimulation is 20 to 30 minutes with the frequencies set at 2Hz and
4 100Hz. (13, 14) Based on these parameters, it is impractical to be manipulating
5 the acupuncture needles manually for 20-30 minutes and also be consistent.
6
7 With EA one can set both parameters precisely at every treatment. EA may be
8 measured objectively and is easier to control and standardize than MA.
9
10
11
12
13
14
15
16
17
18
19
20

21 **The Context And Context Effects**

22 There is mounting evidence that acupuncture treatments for chronic pain, such
23 as low back pain,(15, 16) headache,(17, 18) shoulder and neck pain,(19) are
24 effective. However, a recent individual patient data meta-analysis on the use of
25 acupuncture for chronic pain conditions found a small, statistically significant
26 effect size when compared to sham acupuncture. The effect size was larger and
27 statistically significant when compared to usual care controls. (20) This would
28 suggest that as well as the specific needling effects, other factors within the
29 context of the acupuncture treatment play a role in reducing pain, such as the
30 characteristics of the healthcare providers and patients e.g. their beliefs and
31 expectations; the provider-patient interactions as well as how the treatment is
32 administered. (21) The effects that result from the complex interactions of such
33 characteristics are known as the context effect. (22, 23) This effect was
34 demonstrated in a study of pain management in patients with irritable bowel
35 syndrome, showing that an enhanced provider-patient relationship could help
36 alleviate pain. Patients were randomised on to a waiting list (no placebo or
37 interaction with healthcare provider), therapeutic ritual (placebo sham
38 acupuncture with limited interaction) or a supportive relationship (placebo
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

sham acupuncture with enhanced relationship). The supportive relationship produced the most adequate relief of symptoms and enhanced quality of life.(24)

The proposed pilot study will compare the specific effects of the meridian balanced method (BM) electro-acupuncture needling + the context effects of a TCM HC (BMEA treatment), with context effects of a TCM HC (patient-healthcare provider interaction) and standard care. This study will enable us to tease out the different components of acupuncture treatment that contribute to its analgesic effect and to collect important information to inform a future definitive RCT.

Objectives

Primary objective

The primary objective is to determine recruitment and retention rates in NHS Lothian within defined inclusion/exclusion criteria.

Secondary objectives

To determine the effectiveness and acceptability to participants of the proposed methods of recruitment, randomisation, interventions and assessment tools.

Endpoints

Primary endpoints

1. The proportion of eligible patients randomised into the study
2. The proportion of randomised patients who complete all treatment interventions and questionnaires at the final follow-up.

Secondary endpoints

Data on the effectiveness and acceptability of proposed methods of recruitment, randomisation, interventions and assessment tools.

METHODS AND ANALYSIS

Study design

This is a single centre, open, three-armed parallel randomised controlled pilot study comparing a meridian BM electro-acupuncture + TCM HC (Group 1), with TCM HC (Group 2) and SC (Group 3), (Figure 1), using a mixed methods approach.⁽²⁵⁾ It includes quantitative method using validated questionnaires and qualitative method using focus groups post-week 12 questionnaire completion, as well as field notes and a reflexive diary.

Delivery of intervention in Groups 1 and 2

The following descriptions of our study interventions adhered to guidelines in the “Revised Standards for Reporting Interventions in Clinical Trial of Acupuncture (STRICTA): Extending the CONSORT Statement”.⁽²⁶⁾

The PI (OTC) will deliver all eight BMEA + TCM HC interventions for Group 1 and TCM HC for Group 2 within the same setting in NHS Lothian. The first intervention for both Groups will last approximately 60 minutes. Subsequent 7 interventions for both groups will last no longer than 40 minutes. All participants will receive twice weekly interventions for 4 weeks. Participants in Group 2 will not receive the meridian BM electro-acupuncture. With permission from the participants, all interventions in Groups 1 and 2 will be audiotaped to ensure standardisation of procedures and techniques.

All participants in Groups 1, 2 and 3 will complete the questionnaires at weeks 0, 4, 8 and 12, and will be invited to the Focus Group discussions.

1
2
3 Similarly, Group 1 participants will complete the questionnaires at weeks 0, 4, 8
4 and 12, and will be invited to the Focus Group discussions.
5
6
7
8

9
10 TCM HC (Groups 1 and 2)

11 *Individualised Traditional Chinese Medicine Health Consultation (TCM HC)*

12 For Groups 1 and 2 will share the same approach to the TCM HC. The initial TCM
13 HC will be based on Chinese medicine theory that typically includes history
14 taking: inquiring, listening and inspection of the tongue. Each participant will
15 receive individualised advice based on the specific needs and presenting
16 symptoms. Dietary advice based on Chinese Medicine nutrition and other
17 appropriate self-care skills, such as breathing techniques and physical activities
18 maybe be recommended and modified to accommodate the participant's
19 changing pattern of pain, sleep, level of anxiety, or other health needs. Breathing
20 techniques involve getting the participant to focus her attention on each breath
21 in and out. No herbal medicine therapy will be prescribed.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 *Individualised and systematic acupuncture point selections*

40
41 Step 1: Diagnose the affected/sick meridian(s).

42 This first fundamental and very important step requires the acupuncturist to
43 instruct the patient to indicate where the pain is located so that the affected
44 meridian(s) can be diagnosed accurately.
45
46
47
48
49
50
51

52 Step 2: Identify the balancing meridian(s) based on the 5 systems:

53 Once the affected meridian(s) is/are identified, one of the following meridians
54 can be chosen to balance the affected meridian(s):
55
56
57
58

- 59 • System 1: Foot Taiyin (Name Sharing meridian)

- System 2: Foot Taiyang (Branching meridian)
- System 3: Hand Yangming (Interior/Exterior)
- System 4: Foot Taiyang (Clock Opposite)
- System 5: Foot Jueyin (Clock Neighbour)

Step 3: Acupuncture point(s) selection for treatment

Once the balancing meridian has been selected, step 3 involves locating the therapeutic points along the balancing meridian by using the Mirror or the Image Method. The acupuncturist will palpate for the most tender and tight point(s) (ashii points) along the balancing meridian. The ashii point(s) is/are the therapeutic point(s) if upon pressing the point(s), the patient reports that the pain has been reduced. Thus point selections are based on the steps outlined and not on TCM pattern diagnosis.

Step 4: Connecting the battery operated AS SUPER 4 digital stimulator to the acupuncture needles

The negatively charged, black lead (to stimulate) will be connected to the acupuncture needle inserted in the point that gave the most pain relief, while the positively charged lead (red) will be connected to another needle inserted in the same area. We will use the "AS SUPER 4" Electro-stimulator (Manufacturer: Schwa-medico, Germany) with four outputs. The electro-stimulator emits a square wave of low frequency (2 Hz) for 3-second alternating with high frequency (100 Hz). Program 2 will be selected and the duration of treatment will be no shorter than 20 minutes and no longer than 30 minutes. These parameters are based on the work of Han and his group.⁽²⁷⁾ The intensity of the electrical stimulation will be adjusted based on the participant's feedback, to produce a strong sensation without pain or discomfort.

Depth of needle insertion

The depth of the needle insertion will be adapted to the thickness of the muscles and subcutaneous fatty tissue. For example, for the gluteal muscle, typically a 0.30 mm x 75 mm (3 inches) long the needle will be inserted to a depth of between 1.0 to 2 inches. For the forearm, typically a 0.18mm x 30mm (1.20 inches) will be inserted to a depth of about 0.25 to 0.75 inch. The number of needles inserted will be individualised. We will use Dong Bang (Korea) and Aculine needles (China).

GROUP 3 – Standard Care (SC)

Participants will follow their standard care as given by their clinician. Standard care is defined here as care and treatment that patients would normally receive at The Pelvic Pain Service, NHS Lothian: oral analgesics, neuromodulators such as anti-convulsants and anti-depressants, hormonal approaches, counselling/behavioural therapy or surgical interventions when indicated. The Pelvic Pain Service consists of Consultant Gynaecologist, Anaesthetist specialising in pain, a Psychologist and a Specialist Nurse. The participants will not receive the meridian BM electro-acupuncture treatment or the TCM HC

Subjects

Thirty (30) women (aged greater than or equal to 18 years) with a history of CPP will be recruited.

Sample size

We believe that a sample size of 30 patients is appropriate for a pilot study and will allow estimation of percentage rates of recruitment and retention to within a standard error of at most 10%.

Inclusion criteria

- Chronic pelvic pain longer than 6 months duration
- Average numerical pain score of at least 4 out of 10 in the previous week
- Able and willing to comply with intervention
- Women aged 18 and above

Exclusion criteria

- Pregnancy
- Malignancy
- Severe bleeding disorders (e.g. Type 2, 3 Von Willebrand disease)
- Regular anticoagulant administration
- Severe needle phobia
- A history of seizures
- A pace-maker in situ
- Moderate to severe psychiatric illness (currently under the care of a Psychiatrist)
- Treatment with electro-acupuncture and meridian BM within the last 6 months

Randomisation procedure

We will use an envelope randomisation system created by our statistician. There will be 30 sealed envelopes: 10 meridian BMEA + TCM HC (Group 1), 10 TCM HC (Group 2) and 10 SC (Group 3). The envelopes are randomly assigned a number from 1-30. At the start of the study, the first participant who passes the screening will receive envelope number 1; and the second will receive the envelope number 2 and so on. The envelope will be opened in front of the participant by a member of the research team who screens the participant. If randomised into

either Groups 1 or 2, the participant will receive the appropriate treatment on the same day. If randomised into Group 3, the participant will be instructed to continue the NHS standard care. There will be no stratification.

Intervention

Eligible women will be randomised into meridian BMEA + TCM HC (Group 1), TCM HC (Group 2), or SC (Group 3). Participants in Group 1 will receive 8 interventions: twice a week x 4 weeks. Participants in Group 2 will receive 8 TCM HC: twice a week x 4 weeks. Participants in Group 3 will receive optimal standard care. (Table 4) With permission from the participants, all interventions in Groups 1 and 2 will be audiotaped to ensure standardisation of procedures and techniques.

Table 4: Study Intervention Schedule

		Group 1	Group 2	Group 3
	Baseline WK 0	BMEA +TCM HC	TCM HC alone	Standard Care
	Week 1	Twice Weekly	Twice Weekly	SC
	Week 2	Twice Weekly	Twice Weekly	SC
	Week 3	Twice Weekly	Twice Weekly	SC
	Week 4	Twice Weekly	Twice Weekly	SC
Total	4 Weeks	8 Interventions	8 Interventions	SC

Acupuncturist Information

The PI (OTC) completed 2196 hours of acupuncture training and obtained a Masters of Science Degree in Acupuncture at an accredited school in New York City, USA. She is trained in four styles of acupuncture: traditional Chinese medicine, Kiiko Matsumoto Japanese style, Five Element and the meridian

1 balanced method. She studied electro-acupuncture as part of her acupuncture
2 training and at the British Medical Acupuncture Society (BMAS). She has over 10
3 years of experience using Five Element acupuncture to address psycho-
4 emotional issues and the meridian balanced method acupuncture for pain
5 management in hospital settings such as the New York University Cancer
6 Institute and Royal Infirmary of Edinburgh, UK. She is a Professional Registered
7 Nurse, a National Board Certified Acupuncturist and Chinese medicine herbalist
8 in New York State, USA. She is also Professional Registered Nurse in the United
9 Kingdom.

20 **Data collection**

21 **Screening**

22 Eligible women will be consented and screened by a member of the research
23 team. They will be randomised when they have passed screening. All data will
24 be recorded on a case record form (CRF) and transferred to a secure database.

25 **Assessment tools**

26 Before randomisation, a questionnaire (Baseline week 0) will be given to all
27 participants. This will include the following validated tools:

- 28 1. Visual Analog Scale (VAS scale)
- 29 2. Brief Pain Inventory (BPI)
- 30 3. Hospital Anxiety and Depression Scale (HADS)
- 31 4. Quality Of Life: SF 12
- 32 5. Sexual Activity Questionnaire (SAQ)
- 33 6. Pain Catastrophising Questionnaire (PCQ)
- 34 7. Work Productivity & Activity Impairment Questionnaire (WPAIQ)

35 The set of questionnaires at baseline (week 0) will include participants'
36 demographic and relevant clinical information. The same questionnaire will be

1 posted to all participants at weeks 4, 8 and 12 with an addressed envelope
2 enclosed.
3
4
5
6
7

8 **Focus groups**

9
10 Three focus group discussions will be conducted after questionnaires in week
11 twelve are completed. All participants from the Groups 1, 2 and 3 will be sent a
12 letter of invitation to the focus group discussions. To ensure a high turnout, a
13 week before the designated date of the respective focus group discussions, a
14 member of the research team will contact each participant to encourage them to
15 attend. In order not to bias the group discussions, the PI (OTC) who provides the
16 interventions will not be conducting the focus groups. A separate member of the
17 research team will conduct the three focus group discussions lasting
18 approximately 60 minutes each. A content guide will be used in each group to
19 focus the discussions,(28) which will provide additional data relevant to the
20 study. The topic guide will focus on questions that will explore the participants'
21 perceived benefits or otherwise of the BMEA treatment (Group 1), TCM Health
22 Consultation (Group2) and NHS standard care (Group 3). The focus groups will
23 provide in-depth exploration of how and if the perceived benefits affect the
24 quality of their lives, such as sleep quality, energy levels and sexual activities.
25 The discussions will be audiotaped, transcribed and thematically analysed.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 **Field notes and a reflexive diary**

49 The PI will keep field notes and a reflexive diary during the course of the study.
50 After each intervention the PI will write notes related to her own observation of
51 salient events, discussions, remarks or behaviours that provide more
52 information about the participant and her experience of pain, as well as the
53 possible impact or otherwise of the intervention. For example, the PI might
54
55
56
57
58
59
60

1 notice changes in facial colour or expression when a participant describes how
2 the chronic pelvic pain impacted her life; or a participant who started a
3 treatment intervention apparently agitated but who is looking calmer at the
4 close of the session. Such data can add scope and depth as well as illuminate the
5 different aspects of the interventions and the patient-healthcare provider
6 interactions that might not be captured otherwise. In her reflexive diary the PI
7 will make a note of her thoughts, feelings, and insights of such observations. This
8 reflexive practice involves the PI to be introspective, conscious of her role,
9 reactions and assumptions she brings to the intervention and the research
10 process.(29)
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 **Adverse events**

28 When administered by an appropriately trained and qualified acupuncturist,
29 electro-acupuncture is safe and serious adverse events (SAEs) are not
30 anticipated. However, any SAEs that occur during the study will be reported in
31 the participant's medical record and followed up until resolution of the event.
32 We will also report it to the ACCORD Research Governance
33 (www.accord.ed.ac.uk) and Quality Assurance Office based at the University of
34 Edinburgh within 24 hours. After randomisation, participants in Groups 1 and 2
35 will be instructed to contact a member of the clinical research team if they have
36 an event that necessitates hospitalisation, or results in significant disability or
37 incapacity. In addition, they will be asked about the occurrence of adverse
38 effects at every of the 8 visits during the study. Open-ended and non-leading
39 verbal questioning of the participant will be used to enquire about adverse
40 events, or if they have been admitted to hospital. If there is any doubt as to
41 whether a clinical observation is an AE, the event will be recorded.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

End of study

The end of study is defined as the last participant's last visit.

Proposed analyses

Determine recruitment and retention rates

The recruitment rate will be calculated from the number of eligible patients in the participant log. An acceptable recruitment rate is about 50%. We aim to retain 90% of those recruited to the study. If retention rates are low, we will explore the reasons why at the post study focus group discussions. Information obtained in the discussions will be used to improve compliance in any future study.

Confidence intervals will be calculated for the estimates of rates of recruitment, retention and unanswered questions. The study is not powered to allow comparisons between the randomised groups, and outcomes in each group will just be summarised rather than being compared by formal statistical tests.

Data from the focus groups will be analysed thematically. Thematic analysis aims to highlight and record patterns or themes within a set of data. Such themes capture a certain phenomenon and could be related to the specific research questions or shed light on a specific salient event. Thematic analysis is commonly used in analysis in qualitative research.

Effectiveness and acceptability of proposed methods of recruitment, randomisation, BMEA treatments, TCM HC and assessment tools

Effectiveness will be measured by reductions in pain and associated symptoms such as sleep disturbances, anxiety or depression, that are covered in the

1 questionnaires. Additional information on effectiveness, not covered in the
2 questionnaires, will be captured in the focus groups. The appropriateness of
3 assessment tools used can be assessed through examination of data completion
4 and patterns of missing data. The focus groups will be complementary to
5 understanding if the tools chosen are appropriate and will also provide
6 information on acceptability of recruitment, randomisation and the treatments
7 themselves.
8
9
10
11
12
13
14
15

21 **ETHICS AND DISSEMINATION**

22 Ethical approval has been obtained from the Scotland Research Ethics
23 Committee (REC 14/SS/1022). Data will be presented at international
24 conferences and published in peer-reviewed journals. We will make the
25 information obtained from the study available to the public through national
26 bodies and charities. Participants will be informed of the result of the trial via
27 the Pelvic Pain Clinic, NHS Lothian.
28
29
30
31
32
33
34
35
36
37
38

39 **DISCUSSION**

40 We believe that a definitive evaluation of the effectiveness of the meridian BM
41 electro-acupuncture treatment in the management of CPP requires a multicentre
42 randomised controlled trial (RCT). We anticipate potential difficulties in a large
43 RCT in acupuncture for chronic pain and therefore we have designed this pilot
44 study to evaluate its feasibility.
45
46
47
48
49
50
51
52
53
54

55 Both MA (30) and EA (31, 32) are safe when performed by appropriately trained
56 acupuncturists. However, because of some theoretical safety concerns, we have
57
58
59
60

1 erred on the side of caution to exclude for example, patients who have a history
2 of seizures or have an implanted pace maker.
3
4

5
6
7 According to Chinese medicine theory, pain results from blocked meridians
8 leading to an imbalance in the system. On the surface of the body is a network of
9 12 meridians (6 yin and 6 yang) that connect acupuncture points together.(33)
10 Theoretically, these meridians act as a conduit between the surface of the body
11 and the internal organs. The meridian BM method acupuncture treats pain by
12 balancing these meridians, for example using a “healthy” yin meridian to balance
13 a “blocked” yang meridians. (9) However there are considerable skepticisms and
14 controversies surrounding these theories and the existence as physical entities
15 of acupuncture points and the meridian system. Despite efforts to understand
16 these systems, there are continued disagreements as to what they constitute.(13,
17 34) Indeed, the PI (OTC) argues that it is more useful to view these systems as a
18 conceptual framework that guides the clinical practice of acupuncture, rather
19 than to argue if they exist. Tangentially related to this view is work undertaken
20 by Langevin whereby it is hypothesized that acupuncture points and meridians
21 have correspondence to the connective tissue (35) and not as illustrated in
22 Chinese medicine text.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 A survey of the literature indicates that this is the first study to investigate the
47 effectiveness of the meridian BM electro-acupuncture treatment for chronic
48 pelvic pain in women using a mixed methods approach. The mixed methods
49 approach utilises validated questionnaires and focus group discussions, field
50 notes and a reflexive diary. Undertaking a mixed methods approach is one of the
51 strengths of the study because we are examining the feasibility of studying a
52 complex intervention, which involves a number of phenomena, which include:
53
54
55
56
57
58
59
60

1 TCM health consult, electro-acupuncture and the context effect. Alongside an
2 understanding of participants' perceived benefits or otherwise of the
3 interventions, this methodology will also help us to understand the role of the
4 researcher in the study intervention. The focus group discussions will capture
5 participants' subjective experiences of the study intervention.
6
7
8
9
10
11

12
13
14 It is generally considered that the gold standard in effectiveness of RCTs is the
15 use of a placebo control for the study intervention. However, our pilot study
16 does not employ a placebo (sham acupuncture treatment) for several reasons. A
17 considerable body of evidence from large-scale effectiveness studies has
18 demonstrated that sham acupuncture treatments as controls are problematic.
19 For some chronic pain conditions, the observed effects of acupuncture
20 treatments are larger in usual care controls when compared with sham controls.
21 This might suggest that sham acupuncture treatments have physiological effects,
22 and are thus not inert. Past sham controlled studies have employed techniques
23 such as shallow needling, and needling with a retractable needle or
24 toothpick.(15, 36) Such techniques create a sensation not dissimilar to light
25 touch which has some data to show that it has physiological effects.(37) It is also
26 conceivable and probable that shallow needling and needling with a retractable
27 needle elicit similar physiological effects as deep needling. These sham
28 acupuncture techniques are therefore inappropriate. We feel that until better
29 sham techniques are available, it is prudent to design a study that does not
30 employ a placebo control.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52
53
54
55 Context effects such as expectancy (38) treatment rituals (39) or patient-
56 provider interactions (24, 40) have been shown to have an impact on the
57 experience of pain. These may have confounded past studies and might explain
58
59
60

1 the small effect sizes when sham acupuncture treatments were compared to true
2 acupuncture treatments. Attempting to separate the context effects of
3 acupuncture treatment from the specific effects of acupuncture needling
4 presents a major challenge in this area of research. In response, we have
5 designed a three arm RCT to address these challenges. The first arm includes
6 acupuncture needling, electro-stimulation (specific effects of needling) and the
7 patient-healthcare provider interactions (context effects) via a traditional
8 Chinese medicine consult (TCM HC). Group 2, (participants receive only TCM
9 HC) controls for the patient-healthcare provider interactions (context effect).
10 Participants in Group 3 (standard care) will receive the standard NHS care for
11 CPP. Having these 2 control groups is likely to yield the true effect size of the
12 specific effect of electro-acupuncture needling and the non-specific (context
13 effect) of the patient-healthcare provider interactions. We acknowledge that this
14 pilot study is investigating only one aspect of the several context effects of
15 acupuncture treatment. However, we believe that understanding the clinical
16 outcome of the patient-healthcare provider relationship will create a critical
17 mass of literature to influence the education of future generations of healthcare
18 professionals. The UK SIGN 136 guideline for the management of chronic pain
19 acknowledged that while preliminary data showed that the nature of such a
20 relationship could influence clinical outcome, there are not enough high quality
21 studies to recommend widespread training.(41) (Management of chronic pain.
22 Edinburgh: SIGN; December 2013]. Available from URL: <http://www.sign.ac.uk>. Accessed March
23 2015)

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
In assessing the outcome of the interventions, we have chosen validated
assessment tools rather than using TCM outcome measures. This is because
there are no standardised or validated TCM outcome measures. Arguably, better

1 known validated questionnaires might be more meaningful within a biomedical
2 setting than TCM outcome measures.
3
4
5
6

7
8 In conclusion, our pilot study protocol will enable us to determine the retention
9 and recruitment rate as well as the patients' experience of the study
10 intervention. It will help us gain better insight into the impact of meridian BM
11 electro-acupuncture needling and the patient-practitioner relationship on
12 chronic pelvic pain in women.
13
14
15
16
17

18 19 20 21 **AUTHORS' CONTRIBUTIONS**

22
23 OTC: research, contribution of original material, editing and approval of final
24 manuscript; HODC, AH, MF: research, contribution of original material, editing
25 and approval of final manuscript; RE, EH: editing and approval of final
26 manuscript
27
28
29
30
31

32 33 **FUNDING**

34
35 This work is partly supported by the Barbour Watson Trust and Edinburgh
36 Palliative and Supportive Care Research Fund.
37
38
39
40

41 42 **COMPETING INTERESTS**

43
44 No, there are no competing interests.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference List

1. Daniels J, Khan KS. Chronic pelvic pain in women. *BMJ*. 2010;341.
2. Latthe P, Latthe M, Say L, et al. WHO systematic review of prevalence of chronic pelvic pain: a neglected reproductive health morbidity. *BMC Public Health*. 2006;6(1):177.
3. Daniels J, Gray R, Hills RK, et al. Laparoscopic uterosacral nerve ablation for alleviating chronic pelvic pain: A randomized controlled trial. *JAMA*. 2009;302(9):955-61.
4. Howard FM. The role of laparoscopy as a diagnostic tool in chronic pelvic pain. *Best Practice & Research Clinical Obstetrics & Gynaecology*. 2000;14(3):467-94.
5. Cheong Y, Stones WR. Chronic pelvic pain: aetiology and therapy. *Best Pract Res Clin Obstet Gynaecol*. 2006;20(5):695-711.
6. Tan R. Dr. Tan's Strategy of Twelve Magical Points. San Diego California. 2003.
7. Unschuld P. Huang Di Nei Jing Su Wen: Nature, Knowledge, Imagery in an Ancient Chinese Medical Text. California, USA: University of California Press; 2003.
8. McCann H, Ross, H. Practical Atlas of Tung's Acupuncture. 2nd ed. Germany: Verlag Muller & Steinicke Munchen; 2013.
9. Twicken D. I Ching Acupuncture: The Balance Method. Philadelphia, United States: Singing Dragon; 2012.
10. Tan R. Acupuncture 1, 2, 3 For Back Pain 2008 Jan 2009.
11. Dun AC. The Yellow Emperor's Inner Classic, Spiritual Pivot (Huang Di Nei Jing Su Wen Jiao Zhu Yu Yi). Tianjin, China: Tianjin Science and Technology Press; 1989.
12. Dhond RP, Kettner N, Napadow V. Neuroimaging acupuncture effects in the human brain. *J Altern Complement Med*. 2007;13(6):603-16.
13. Ulett GH, SP, Han, JS. Electroacupuncture: mechanisms and clinical application. *Biol Psychiatry*. 1998;44(2):129-38.
14. Thomas M, Lundberg T. Importance of modes of acupuncture in the treatment of chronic nociceptive low back pain. *Acta Anaesthesiol Scand*. 1994;38(1):63-9.
15. Haake M MHS-BC, et al. German acupuncture trials (gerac) for chronic low back pain: Randomized, multicenter, blinded, parallel-group trial with 3 groups. *Arch Intern Med*. 2007;167(17):1892-8.

16. Brinkhaus B, Witt CM, Jena S. et al. Acupuncture in patients with chronic low back pain: A randomized controlled trial. *Arch Intern Med.* 2006;166(4):450-7.
17. Melchart D, Streng A, Hoppe A, *et al.* The acupuncture randomised trial (ART) for tension-type headache--details of the treatment. *Acupunct Med.* 2005;23(4):157-65.
18. Endres H, Bowing G, Diener HC. et al. Acupuncture for tension-type headache: a multicentre, sham-controlled, patient-and observer-blinded, randomised trial. *J Headache Pain.* 2007;8(5):306-14.
19. Witt C, Jena S, Brinkhaus B. et al. Acupuncture for patients with chronic neck pain. *Pain.* 2006;125(1-2):98-106.
20. Vickers AJ, Cronin AM, Maschino AC, et al. Acupuncture for chronic pain: Individual patient data meta-analysis. *Arch Intern Med.* 2012;172(19):1444-53.
21. Benedetti F. How the doctor's words affect the patient's brain. *Eval Health Prof.* 2002;25(4):369-86.
22. Price DD, Finniss DG, Benedetti F. A Comprehensive Review of the Placebo Effect: Recent Advances and Current Thought. *Annu Rev Psychol.* 2008;59(1):565-90.
23. Miller FG, Kaptchuk TJ. The power of context: reconceptualizing the placebo effect. *J R Soc Med.* 2008;101(5):222-5.
24. Kaptchuk T, Kelley, JM, Conboy, L. et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. *BMJ.* 2008;336(7651):999-1003.
25. Creswell J, Clark VLP. *Designing and Conducting Mixed Methods Research.* 2 ed: Sage 2011: 2-5.
26. MacPherson H, Altman DG, Hammerschlag R, *et al.* Revised standards for reporting interventions in clinical trials of acupuncture (STRICTA): extending the CONSORT statement. *Journal of Evidence - Based Medicine.* 2010;3(3):140-55.
27. Han JS, Terenius L. Neurochemical basis of acupuncture analgesia. *Annu Rev Pharmacol Toxicol.* 1982;22:193-220.
28. Morgan DL. *Focus Groups As Qualitative Research.* Second ed. London: Sage Publications; 1997: 47-48.
29. Finlay L. "Outing" the researcher: The provenance, process, and practice of reflexivity. *Qual Health Research* 2002, 12:531. *Qualitative Health Research [Internet].* 2002.
30. MacPherson H, Thomas K, Walters S. et al. The York acupuncture safety study: prospective survey of 34 000 treatments by traditional acupuncturists. *BMJ.* 2001;323(7311):486-7.
31. Cummings M. Safety aspects of electroacupuncture. *Acupunct Med.* 2011;29(2):83-5.

- 1 32. Thompson JW, Cummings M. Investigating the safety of
2 electroacupuncture with a Picoscope. *Acupunct Med*. 2008;26(3):133-9.
3
- 4 33. Deadman P, Al-Khafaji M, & Baker K. A Manual of Acupuncture. England,
5 UK: Journal of Chinese Medicine Publications; 2001:13-16.
6
- 7 34. Pandolfi M. The autumn of acupuncture. *Eur J Intern Med*. 2012;23(1):31-
8 3.
9
- 10 35. Langevin HM, Churchill DL, Wu JR, *et al*. Evidence of connective tissue
11 involvement in acupuncture. *FASEB J*. 2002;16(6):872-+.
12
- 13 36. Langevin H, Wayne PM, MacPherson H. *et al*. Paradoxes in Acupuncture
14 Research: Strategies for Moving Forward. *Evid Based Complement Alternat Med*.
15 2010.
16
- 17 37. Lund I, Lundeberg T. Are minimal, superficial or sham acupuncture
18 procedures acceptable as inert placebo controls? *Acupunct Med*. 2006;24(1):13-
19 5.
20
- 21 38. Kong J, Kaptchuk TJ, Polich G, *et al*. Expectancy and treatment
22 interactions: a dissociation between acupuncture analgesia and expectancy
23 evoked placebo analgesia. *Neuroimage*. 2009;45(3):940-9.
24
- 25 39. Kaptchuk TJ. The placebo effect in alternative medicine: can the
26 performance of a healing ritual have clinical significance? *Ann Intern Med*.
27 2002;136(11):817-25.
28
- 29 40. Paterson C, Dieppe P. Characteristic and incidental (placebo) effects in
30 complex interventions such as acupuncture. *Br Med J*. 2005;330(7501):1202-5.
31
- 32 41. Management of Chronic Pain, <UK SIGN136.pdf>.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flow of participants through the study
297x419mm (300 x 300 DPI)



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___ 1 ___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___ 3 ___
	2b	All items from the World Health Organization Trial Registration Data Set	___ N/A ___
Protocol version	3	Date and version identifier	___ All ___
Funding	4	Sources and types of financial, material, and other support	___ 23 ___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___ 1 and 23 ___
	5b	Name and contact information for the trial sponsor	___ 17/18 ___
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___ N/A ___
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	___ N/A ___

1
2
3 **Introduction**
4

5	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant	_____ 3-8 _____
6	rationale		studies (published and unpublished) examining benefits and harms for each intervention	
8		6b	Explanation for choice of comparators	_____ 9 _____
10	Objectives	7	Specific objectives or hypotheses	_____ 8 _____
12	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),	
13			allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	_____ 9 _____
16	Methods: Participants, interventions, and outcomes			
18	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will	_____ 9 _____
19			be collected. Reference to where list of study sites can be obtained	
21	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and	_____ 13 _____
22			individuals who will perform the interventions (eg, surgeons, psychotherapists)	
24	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be	_____ 9-12 _____
25			administered	
27		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose	_____ N/A _____
28			change in response to harms, participant request, or improving/worsening disease)	
30		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence	_____ N/A _____
31			(eg, drug tablet return, laboratory tests)	
33		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	_____ N/A _____
35	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood	_____ 8-9 _____
36			pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg,	
37			median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen	
38			efficacy and harm outcomes is strongly recommended	
41	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for	_____ 16 _____
42			participants. A schematic diagram is highly recommended (see Figure)	

1				
2				
3	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	_____13_____
4				
5				
6	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	_____N/A_____
7				

8 **Methods: Assignment of interventions (for controlled trials)**

9 Allocation:

10				
11				
12	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	_____N/A_____
13				
14				
15				
16				
17				
18	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	_____14_____
19				
20				
21				
22	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	_____14_____
23				
24				
25	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	_____N/A_____
26				
27				
28		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	_____N/A_____
29				
30				
31				

32 **Methods: Data collection, management, and analysis**

33				
34	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	_____15-16_____
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	_____16_____
40				
41				
42				
43				
44				
45				

1				
2				
3	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	___15___
4				
5				
6				
7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	___18___
8				
9				
10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	___18-19___
11				
12		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	___N/A___
13				
14				
15				
16	Methods: Monitoring			
17				
18	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	___19___
19				
20				
21				
22				
23		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	___N/A___
24				
25				
26	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	___19___
27				
28				
29	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	___N/A___
30				
31				
32				
33	Ethics and dissemination			
34				
35	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	___3___
36				
37				
38	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	___N/A___
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	___15___
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	___N/A___
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	___15___
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	___24___
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	___17___
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	___17___
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	___3___
	31b	Authorship eligibility guidelines and any intended use of professional writers	___23___
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	___N/A___
Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	___App 1, 2___
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	___N/A___

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.